Please assess the completion status of the following clinical trial:

Trial Title: Brain Effects of Escitalopram and Citalopram Using fMRI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male aged 21 to 50 years.~* Capable of providing informed consent.~* Has an established residence and phone.~Exclusion Criteria:~* Meets DSM-IV criteria for an Axis I or II disorder.~* History of substance dependence or abuse within the past month.~* Use of NSAID's, beta blockers, calcium channel blockers, antidepressants, antipsychotic medications, lithium or other medication which in the opinion of the investigator would alter vascular responsivity.~* Regular use of sedative hypnotic or narcotic medication, or other medication that might affect the individual's perception of visual stimuli.~* History of cataracts or significant visual impairment.~* A medical condition, which in the opinion of the investigator is likely to affect the individual's perception of the visual stimuli or vascular response.~* Participation in a research protocol that included administration of medication within the past 3 months.~* Cigarette smoking.

- Gender: MALE
- Minimum Age: 21 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Escitalopram (Type: ACTIVE_COMPARATOR): One week of escitalopram at 10 mg followed by one week at 20 mg in healthy volunteers.
- Citalopram (Type: ACTIVE_COMPARATOR): One week of citalopram at 20 mg followed by one week at 40 mg in healthy volunteers.
- Placebo (Type: PLACEBO_COMPARATOR): Two weeks of placebo in healthy volunteers.

Based on this trial design, predict the completion outcome and termination type (if applicable).